Nevanac licensed for diabetic indication

Nevanac (nepafenac) is now indicated to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Diabetic patients have a slightly higher risk of developing macular oedema following ocular surgery
Diabetic patients have a slightly higher risk of developing macular oedema following ocular surgery

In a double-blind, randomised, vehicle-controlled study, patients with diabetes were randomised to receive either nepafenac eye drops or placebo 3 times daily. Medication was initiated the day prior to surgery, and continued on the day of surgery and for up to 90 days of the postoperative period. The study showed that a significantly greater proportion of patients developed macular oedema in the vehicle group (16.7%) than in the nepafenac group (3.2%).

View Nevanac drug record

Further information: Alcon Laboratories UK Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.